Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin

被引:2
作者
Jammah, Anwar Ali [1 ]
机构
[1] King Saud Univ, Dept Med, POB 2925 38, Riyadh 11461, Saudi Arabia
关键词
Indirect comparison; Type; 2; diabetes; Insulin aspart; Glucagon-like peptide 1; Insulin glargine; FIXED-RATIO COMBINATION; GLARGINE; LIXISENATIDE; LIXILAN; PHASE-3;
D O I
10.1016/j.pcd.2020.08.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Fixed-dose combinations of insulin glargine/lixisenatide (IGlarLixi) or insulin degludec/insulin aspart (IDegAsp) constitute treatment intensification in type 2 diabetes mellitus (T2D). Objectives: Compare efficacy and safety of IGlarLixi and IDegAsp (as intensification from basal insulin), by indirect comparison of phase III trials, in the absence of head-to-head trials. Study eligibility criteria: Studies comparing treatment intensification by once-daily IDegAsp or IGlarLixi to basal insulin. Data were extracted from two trials (BOOST: Intensify-Basal and LixiLan-L) retained for analysis. Synthesis methods: Treatments were compared in terms of estimated treatment difference (ETD) in glycated haemoglobin (HbA1c), fasting and postprandial plasma glucose (FPG and PPG) change from baseline; in addition to hypoglycaemia incidence and weight changes. Results: In a fixed-effect model examining HbA1c control, IGlarLixi was more effective than IDegAsp in reducing HbA1c (ETD 0.53%, P<0.0001]), PPG (ETD 2.65%, P<0.0001), and body weight (ETD 1.73 kg, P<0.0001). Patients on IGlarLixi were more likely to achieve HbA1c < 7% than patients on IDegAsp (odds ratio [OR] = 0.40, P<0.0001), with lower incidence of hypoglycaemia (OR=1.33, P<0.001). Limitations: Limited number of studies; different baseline HbA1c and FPG. Conclusion: Once-daily IGlarLixi is more efficient than once-daily IDegAsp in controlling HbA1c and PPG and associates with greater weight loss and lower hypoglycaemia incidence. (C) 2020 The Author. Published by Elsevier Ltd on behalf of Primary Care Diabetes Europe.
引用
收藏
页码:132 / 137
页数:6
相关论文
共 25 条
[1]   Evaluation of psychological resistance to insulin treatment in type II diabetic patients [J].
Aleali, Armaghan Moravej ;
Payami, Seyed Peyman ;
Latifi, Seyed Mahmoud ;
Yazdanpanah, Leila ;
Hesam, Saeed ;
Khajeddin, Niloufar .
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2018, 12 (06) :929-932
[2]   Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial [J].
Aroda, Vanita R. ;
Rosenstock, Julio ;
Wysham, Carol ;
Unger, Jeffrey ;
Bellido, Diego ;
Gonzalez-Galvez, Guillermo ;
Takami, Akane ;
Guo, Hailing ;
Niemoeller, Elisabeth ;
Souhami, Elisabeth ;
Bergenstal, Richard M. .
DIABETES CARE, 2016, 39 (11) :1972-1980
[3]   Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA [J].
Billings, L. K. ;
Mocarski, M. ;
Basse, A. ;
Hunt, B. ;
Valentine, W. J. ;
Jodar, E. .
CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 :271-282
[4]   Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin [J].
Blonde, Lawrence ;
Raccah, Denis ;
Lew, Elisheva ;
Meyers, Juliana ;
Nikonova, Elena ;
Ajmera, Mayank ;
Davis, Keith L. ;
Bertolini, Monica ;
Guerci, Bruno .
DIABETES THERAPY, 2018, 9 (03) :1169-1184
[5]   The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials [J].
Bucher, HC ;
Guyatt, GH ;
Griffith, LE ;
Walter, SD .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1997, 50 (06) :683-691
[6]  
Cho K, 2019, DIABETES METAB J
[7]   Insulin initiation in primary care for patients with type 2 diabetes: 3-Year follow-up study [J].
Dale, Jeremy ;
Martin, Steven ;
Gadsby, Roger .
PRIMARY CARE DIABETES, 2010, 4 (02) :85-89
[8]  
Davies MJ, 2018, DIABETOLOGIA, V61, P2461, DOI [10.1007/s00125-018-4729-5, 10.2337/dci18-0033]
[9]   Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents [J].
Davies, Melanie J. ;
Leiter, Lawrence A. ;
Guerci, Bruno ;
Grunberger, George ;
Javier Ampudia-Blasco, F. ;
Yu, Christine ;
Stager, William ;
Niemoeller, Elisabeth ;
Souhami, Elisabeth ;
Rosenstock, Julio .
DIABETES OBESITY & METABOLISM, 2017, 19 (12) :1798-1804
[10]   Twice-daily insulin degludec/insulin aspart effectively improved morning and evening glucose levels and quality of life in patients previously treated with premixed insulin: an observational study [J].
Fujimoto, Kanta ;
Iwakura, Toshio ;
Aburaya, Megumi ;
Matsuoka, Naoki .
DIABETOLOGY & METABOLIC SYNDROME, 2018, 10